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Abstract In humans, short-term supplementation with nitrate
is hypotensive and inhibits platelet aggregation via an nitric
oxide (NO)-dependent mechanism. In the present work, we
analyzed whether short-term treatment with nitrate induces
antithrombotic effects in rats and mice. Arterial thrombosis
was evoked electrically in a rat model in which renovascular
hypertension was induced by partial ligation of the left renal
artery. In mice expressing green fluorescent protein, laser-
induced thrombosis was analyzed intravitally by using confo-
cal microscope. Sodium nitrate (NaNO3) or sodium nitrite
(NaNO2) was administered orally at a dose of 0.17 mmol/
kg, twice per day for 3 days. Short-term nitrate treatment did
not modify thrombus formation in either rats or mice, while
nitrite administration led to pronounced antithrombotic activ-
ity. In hypertensive rats, nitrite treatment resulted in a signif-
icant decrease in thrombus weight (0.50 ± 0.08 mg vs. VEH
0.96 ± 0.09 mg; p < 0.01). In addition, nitrite inhibited ex vivo
platelet aggregation and thromboxane B2 (TxB2) generation
and prolonged prothrombin time. These effects were accom-
panied by significant increases in blood NOHb concentration
and plasma nitrite concentration. In contrast, nitrate did not
affect ex vivo platelet aggregation or prothrombin time and
led to only slightly elevated nitrite plasma concentration. In
mice, nitrate was also ineffective, while nitrite led to decreased
platelet accumulation in the area of laser-induced endothelial
injury. In conclusion, although nitrite induced profound NO-
dependent antithrombotic effects in vivo, conversion of ni-
trates to nitrite in rats and mice over short-term 3-day treat-
ment was not sufficient to elicit NO-dependent antiplatelet or
antithrombotic effects.
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Introduction
For decades, nitrites (NO2
−) and nitrates (NO3
−) were thought
to be stable end-products of nitric oxide (NO) produced by
NO synthase (NOS) (Bryan 2006). Recently, however, a re-
ductive NO3
−-NO2
−-NO pathway has been proposed as a
backup system that acts to maintain NO generation (Kapil
2013).
Compatible with the importance of the reductive pathway
for NO production in vivo, even short-term (3 days) supple-
mentation with NaNO3 (0.1 mmol/kg daily) was shown to
result in a significant increase in plasma NO2
− concentration
in healthy humans and a subsequent fall in diastolic blood
pressure (Larsen 2006). Similarly, short-term (3 days) supple-
mentation with dietary nitrate, given in the form of beetroot
juice to healthy volunteers, not only reduced systolic and di-
astolic blood pressure but also improved endothelial function
and significantly attenuated ex vivo collagen-induced and
ADP-induced platelet aggregation (Webb 2008). Nitrate-
induced effects on blood pressure and platelet aggregation
were correlated with an increase in plasma nitrite concentra-
tion. Furthermore, Kapil et al. (2010) demonstrated that inor-
ganic nitrate given as a single dose (12 or 24 mmol) or in one
shot of beetroot juice (containing 5.5 mmol of nitrate) lowered
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blood pressure. This effect was associated with a dose-
dependent elevation in plasma nitrite concentration as well
as elevated cyclic guanosine monophosphate (cGMP),
confirming that the acute nitrate effect in humans is mediated
by the NO-cGMP pathway (Kapil 2010). Obviously, not only
short-term but also long-term intake of inorganic NO supple-
ments was shown to have beneficial effects on the cardiovas-
cular system of humans (Zand 2011).
An overwhelming body of evidence suggests that the
beneficial effects of nitrate in humans, either upon short-
term or long-term treatment (Zand 2011; Mills 2016), in-
volve the enterosalivary nitrate-nitrite-NO pathway.
Indeed, it has been reported that ingested nitrate is active-
ly transported from blood to the salivary glands and ac-
cumulates in saliva (Tannenbaum 1976; Spiegelhalder
1976; Kortboyer 1994; Qin 2012). Oral bacteria reduces
nitrate into nitrite (Tannenbaum 1974; Ishiwata 1975;
Duncan 1995; Doel 2005; Kapil 2010), which is
swallowed and then absorbed in the intestines, resulting
in elevated plasma nitrite concentration (Lundberg 2004;
Webb 2008; Kapil 2010; Qin 2012). As reviewed by
Lundberg and Weitzberg (2010), nitrate-nitrite conversion
in the human oral cavity is metabolized by specific reduc-
tase enzymes of the commensal bacteria, whereas nitrite-
NO reduction is enhanced by vitamin C, polyphenols, and
cytochrome P450 enzymes. Furthermore, a number of
mammalian nitrite reductase enzymes have been demon-
strated to reduce nitrite to NO, including xanthine oxido-
reductase (XOR) (Cantu-Medellin 2013a,b), hemoglobin
(Hb) (Huang 2005; Larsen 2011; Kahn 2013), mioglobin
(Mb) (Hendgen-Cotta 2014), neuroglobin (Ngb)
(Jayaraman 2011), aldehyde oxidase (AO) (Li 2009), sul-
fite oxidase (SO) (Wang 2010), components of the mito-
chondrial electron transport chain (ETC), and NOS
(Sparacino-Watkins 2014).
Altogether, the evidence suggests that two important path-
ways exist for NO generation: the first from endogenous L-
arginine, involving NO synthase, and the other involving the
reduction of nitrate to nitrite that seems to operate particularly
in the context of endothelial dysfunction or hypoxia/low pH.
A number of reports have suggested that the beneficial
pharmacological effects of nitrate also pertain to rats and mice
(Bouaziz-Keteta 2014; Jiang 2014; Carlström 2015; Roberts
2015). However, it remains unclear whether the reductive
nitrate-nitrite-NO pathway is as effective in laboratory rodents
as it is in humans and whether NO-mediated effects will be
seen after short-term treatment, as in humans (Larsen 2006).
To explore this question, we comprehensively analyzed the
antithrombotic and antiplatelet effects of nitrate as compared
to nitrite and analyzed the conversion of nitrate to nitrite in rats
after 3-day treatment.We also tested the antithrombotic effects
of 3-day treatment with nitrate, as compared with nitrate, in
mice.
Materials and methods
Animals and the induction of renovascular hypertension
Male Wistar rats were purchased from Charles River
Laboratory and housed in the animal house of the
Jagiellonian Centre for Experimental Therapeutics
(JCET), Jagiellonian University (Krakow, Poland), under
a 12-h light/dark cycle. The animals were grouped in
cages as appropriate and had access to sterilized tap wa-
ter and standard rat chow ad libitum. Green fluorescent
protein (GFP)-expressing transgenic mice, based on the
C57BL/6J strain (GFP mice) (Okabe 1997), were pur-
chased from the Centre for Experimental Medicine in
Bialystok. All procedures involving animals were ap-
proved by a bioethics committee and conducted in accor-
dance with the institutional guidelines, which are in com-
pliance with national and international laws, including
EU Directive 2010/63/EU for animal experiments and
the Guidelines for the Care and the Use of Animals in
Biomedical Research (Giles 1987).
The rats were anesthetized with pentobarbital (40 mg/kg,
i.p.). Two-kidney one-clip (2K1C) renovascular hypertension
was induced by partial, standardized clipping of the left renal
artery (Huang 1981). Six weeks following induction of hyper-
tension, mean blood pressure (MBP) was measured by using
the “tail-cuff”method (Panlab, Harvard Apparatus, UE) (Zatz
1990). All rats with elevated blood pressure (SBP/DBP > 140/
90 mmHg) were assigned to the hypertensive group. Sham-
operated (SO) rats served as the control for 2K1C hyperten-
sive rats. They underwent the same surgical intervention with-
out clipping of the renal artery. Hypertensive rats were divided
into groups undergoing experimentally induced arterial
thrombosis in vitro experiments.
Rat model of arterial thrombosis in vivo
The 2K1C rats were anaesthetized with pentobarbital
(40 mg/kg, i.p.) and placed in a supine position on a
heated (37 °C) operating table. Arterial thrombosis was
induced by electrical stimulation of the right common
carotid artery, as previously described (Kramkowski
2012). Briefly, the anode, a stainless steel L-shaped wire,
was inserted under the artery and connected to a constant
current generator. The cathode was attached subcutane-
ously to the hindlimb. The artery was stimulated (1 mA)
for 10 min. Fifty-five minutes after the beginning of stim-
ulation, the segment of the common carotid artery con-
taining the formed thrombus was dissected and opened
lengthwise, and the thrombus was completely removed
and air-dried at room temperature for 24 h. It was then
weighed in a blinded manner.
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Platelet aggregation
Collagen-stimulated platelet aggregation in citrated whole
blood was evaluated by using the impedance method, as de-
scribed previously (Kramkowski 2012), and measured in a
whole blood lumi-aggregometer (Chrono-log, USA). Briefly,
blood samples were collected from nitrate-treated or nitrite-
treated 2K1C rats with electrically stimulated thrombosis.
Samples were collected in 3.13 % trisodium citrate at a vol-
ume ratio of 10:1. After 15-min incubation at 37 °C with
0.9 % NaCl (volume ratio 1:1), collagen (5 μg/ml) was added.
In all aggregation experiments, changes in resistance were
registered for 6 min. The extension of the aggregation curve
at 6 min was expressed as a percentage of the control
response.
Dynamic thromboxane B2 generation
Citrated blood samples from 2K1C rats with electrically stim-
ulated thrombosis were diluted with 0.9 % NaCl at a ratio of
1:1 and stirred in aggregation cuvettes at 37 °C at 1000 rpm.
At 0, 20, 40, and 60 min, samples of stirred blood were drawn
off and mixed with a cold solution of acetylsalicylic acid (final
concentration 500 μM) at a ratio of 1:1. Thromboxane B2
(TxB2) concentrations in the obtained samples were deter-
mined by ELISA, according to the instructions provided by
the kit manufacturer.
Measurement of nitrite, nitrate, and nitrosyl hemoglobin
in blood
Plasma concentrations of nitrite and nitrate were measured
with the nitrate/nitrite analysis system, ENO-20 (Eicom).
ENO-20 employs liquid chromatography with post-column
derivatization by using the Griess reagent. Nitrite and nitrate
were separated from other substances in matrix on NO-PAK
columns (4.6 × 50 mm, Eicom). Nitrate was reduced to nitrite
on a cadmium-copper column (NO-RED, Eicom). Nitrite was
mixed with the Griess reagent to form a purple azo dye in a
reaction coil placed in a column oven at 35 °C, and the absor-
bance of the dye product was measured at 540 nm. The flow
of the mobile phase (Carrier solution, Eicom) was 0.33 ml/
min. The Griess reagent was delivered by pump at a rate of
0.11 ml/min. The plasma sample was precipitated with meth-
anol at a ratio of 1:1 (v/v). Plasma samples were centrifuged at
10,000×g for 10 min. Ten microliters of supernatant was
injected into the HPLC system.
The concentration of nitrosyl hemoglobin wasmeasured by
electron paramagnetic resonance (EPR). EPR spectra of iso-
lated erythrocytes (snap-frozen isolated erythrocytes obtained
from whole blood via centrifugation at 1000×g and 4 °C for
5 min) were recorded in liquid nitrogen (77 K) by using a
Bruker EMX Plus spectrometer operating at X-band, with a
1041HS resonator. The following conditions were used: mi-
crowave power = 15.89 mW, time constant = 81.92 ms, mod-
ulation frequency = 100 kHz, modulation amplitude = 5G,
s can t ime = 20 .48 s , s can wid th = 200G , and
temperature = 77 K. For each sample, 30 individual scans
were averaged. The level of microwave power was deter-
mined from the saturation curve of the EPR signal at the cen-
terline of NOHb, which indicated that the signal was not sat-
urated up to approximately to the level of 16 mW. The over-
lying free radical signals at G = 2 were quantified experimen-
tally and deconvoluted to enhance NOHb signal enhance by
using an in-house algebraic process. NOHb levels were
expressed as EPR amplitude in arbitrary units, normalized to
sample weight (259.6 ± 8.8 mg).
Measurement of coagulation and fibrinolysis parameters
in plasma and blood cell count
Prothrombin time (PT), activated partial thromboplastin time
(aPTT), and fibrinogen (Fg) levels (Clauss method) were de-
termined according to the kit manufacturer’s instructions by
using the Coag-Chrom 3003 apparatus (Bio-ksel, Poland). For
fibrin generation, we used a method described previously (He
2001) and modified by us (Buczko 2003). Briefly, fibrin gen-
eration curves were created by recalcinating rat plasma sam-
ples directly in microplate wells by using CaCl2 (36 mM)
dissolved in Tris buffer (66 mM Tris, 130 mM NaCl, pH
7.4) at 37 °C. Increases in optical density in the wells (as a
result of fibrin generation) were measured with the microplate
reader (Biotec EL808, USA) at 1-min intervals for 9 min and
expressed as the area under the curve (AUC). Time-point
analysis results were calculated as percentages of basal optical
density.
Blood cell count was assessed with an Animal Blood
Counter (ABCVet, Horiba, Germany) in blood collected from
the left ventricles of 2K1C hypertensive rats after thrombus
removal (ex vivo) or untreated 2K1C rats (in vitro
experiments).
Intravital imaging of platelet accumulation after laser
injury of endothelium in mice
GFP mice were anesthetized with ketamine and xylazine
(i.p.). A midline laparotomy incision was made, and then,
the mesentery of the ileum was pulled out of the abdomen
and draped over a plastic mound. The mesentery was contin-
uously perfused with 37 °C-warmed phosphate-buffered sa-
line (PBS) to prevent the vessels from drying. Mesenteric
venules were identified, and endothelial injury was induced
by a 514-nm argon-ion laser (Intelligent Imaging Innovations
GmbH, Germany). The laser beam was aimed at the endothe-
lium through the microscope objective lens, and the intensity
of laser illumination and duration was kept constant (Falati
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2002; Hayashi 2008). Changes in fluorescence intensity were
measured automatically by using Slidebook5.0 software. The
fluorescence intensity of GFP was normalized to the initial
value in each experiment, and then, areas under the curves
were calculated for statistics (Intelligent Imaging
Innovations GmbH, Germany) (Falati 2002; Hayashi 2008).
Administration of NaNO2 and NaNO3
Rats and mice received nitrate or nitrite (0.17 mmol/kg) twice
daily for 3 days (by intragastric gavage); the final dose was
given 20 min before anesthesia. Sterilized tap water (2 ml/kg)
served as a control and vehicle (VEH). The doses of nitrites
and nitrates were chosen on the basis of our earlier experi-
ments, which showed that nitrite at a dose of 0.17 mmol is a
potent, antithrombotic agent with only weak hemodynamic
effects (Kramkowski 2015).
Chemicals and drugs
The following agents were used: sodium nitrite (NaNO2), so-
dium nitrate (NaNO3), calcium chloride (CaCl2), sodium chlo-
ride (NaCl), and Tris buffer (all Sigma-Aldrich, Germany);
pentobarbital (Morbital) from Biovet (Poland); PBS from
Biomed (Poland); collagen from Chrono-log (USA); ready-
to-use kits for blood cell count from HoribaABX
(Germany); oxymetric tests from Ultra Nova Biomedical
(USA); routine laboratory reagents for determining PT,
aPTT, and Fg levels in rat plasma from HemosIL
Instrumentation Laboratory (USA); rat PAI-1 and tissue tPA
ELISA kits from Hyphen BioMed (France); and a TxB2
ELISA kit from ENZO Life Science. All other products were
purchased from Sigma (Gillingham, Dorset, UK).
Statistical analysis
We used analysis of variance (ANOVA), a multiple compari-
son test (for normal distribution), and a Bonferroni correction
for multiple comparisons after a nonparametric test (for non-
normal distribution). A p value <0.05 was considered to indi-
cate significance.
Results
Effects of nitrate and nitrite on thrombus weight in rat
Treatment with nitrate (n = 9) at a dose of 0.17 mmol/kg twice
daily for 3 days (p.o.) did not affect thrombus weight (TW)
(0.83 ± 0.06mg vs. VEH 0.96 ± 0.09mg, n = 11, ns), while an
equimolar dose of nitr i te (n = 9) decreased TW
(TW = 0.50 ± 0.08 mg, p < 0.01, vs. VEH) (Fig. 1).
Effects of nitrate and nitrite on ex vivo platelet function
Treatment with nitrate similarly failed to influence collagen-
stimulated whole blood ex vivo platelet aggregation
(87.50 ± 7.14 % vs. VEH 100 ± 4.46 %, ns), while nitrite
treatment inhibited platelet aggregation (70.54 ± 7.14 % vs.
VEH, p < 0.05) (Fig. 2a). Furthermore, nitrate treatment failed
to affect ex vivo dynamic generation of TxB2 in full blood
assay, while nitrite treatment significantly inhibited generation
of TxB2 (p < 0.05 vs. VEH) (Fig. 2b).
Effects of nitrate and nitrite treatment on NOHb
and nitrate and nitrite concentrations in blood
As expected, nitrate plasma concentration was profoundly in-
creased in rats treated with nitrate (114.45 ± 6.86 μMvs. VEH
13.70 ± 2.41 μM, p < 0.05), while NOHb concentration was
only moderately increased (328 ± 6.0 units/mg vs. VEH
231.9 ± 36 units/mg, ns). In the nitrite-treated group (Fig. 3),
nitrite plasma concentration was markedly increased
(43.71 ± 6.44 μM, p < 0.001, vs. VEH 0.61 ± 0.11 μM), as
was NOHb concentration (27.100 ± 5514 units/mg, p < 0.001,
vs. VEH 231.9 ± 36 units/mg).
Effects on nitrate and nitrite treatment on coagulation
and blood cell count
Nitrate treatment did not influence any of the estimated coag-
ulation parameters, while nitrite decreased fibrin generation
(p < 0.05 and p < 0.01 vs. VEH in point-to-point analysis of
VEH curve) and decreased area under the curve
(88.71 ± 17.44 units2 vs. VEH 171.94 ± 15.79 units2,
p < 0.05) (Fig. 4a, b). On the other hand, as shown in
Table 1, nitrite treatment slightly prolonged PT but did not
change other coagulation parameters such as APTT, TT, fi-
brinogen level, and QUICK. Neither nitrate nor nitrite influ-
enced blood cell count (Table 2).
Fig. 1 Lack of antithrombotic effect of nitrate compared to nitrite in
hypertensive (2K1C) rats after oral administration twice daily for
3 days (0.17 mmol/kg); **p < 0.01 vs. VEH
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Effects of nitrate and nitrite treatment on in vivo platelet
accumulation in mice: intravital imaging
Nitrate treatment did not influence platelet accumulation in the
area of the laser-injured endothelium in GFP mice
(90.26 ± 24.45 units2 vs. VEH 95.76 ± 19.66 units2, ns), while
nitrite treatment decreased the AUC in the time-course curve
of platelet accumulation (49.03 ± 6.31 units2 vs. VEH
95.76 ± 19.66 units2, p < 0.05) (Figs. 5a, b and 6a–c).
Fig. 3 Effect of nitrite and nitrate
on a nitrite plasma concentration
and b NOHb content in blood in
hypertensive (2K1C) rats (oral
administration twice daily for
3 days, 0.17 mmol/kg);
***p < 0.001 vs. VEH
Fig. 2 Lack of ex vivo
antiplatelet effect of nitrate
compared to nitrite: a whole
blood collagen-stimulated platelet
aggregation and b dynamic TxB2
generation in hypertensive
(2K1C) rats after oral
administration twice daily for
3 days (0.17 mmol/kg); *p < 0.05
vs. VEH
Naunyn-Schmiedeberg's Arch Pharmacol (2017) 390:85–94 89
Discussion
In the present work, we demonstrated for the first time that a
low dose of nitrate (0.17 mmol/kg, p.o., bid), given as a short-
term 3-day treatment, did not display antithrombotic effects in
rats and in mice. In contrast, an equimolar dose of nitrite
decreased thrombus weight, inhibited ex vivo collagen-
stimulated platelet aggregation, inhibited platelet TxB2 gener-
ation in full blood assay, and inhibited coagulation.
Furthermore, we found that nitrite, but not nitrate, decreased
fibrin generation. Since the overall coagulation potential de-
pends on active phospholipid surfaces that are exposed by
activated platelets, we suggest that nitrite decreases coagula-
tion by an indirect mechanism that is dependent on platelet
inhibition, rather than by direct inhibition of clotting factors.
Thrombus weight and nitrite plasma concentration correlated
with NOHb content in blood, suggesting involvement of NO
in the antithrombotic effects of nitrite. Similarly, in mice, ni-
trate was ineffective, while nitrite decreased platelet accumu-
lation in the area of laser-induced endothelial injury. Although
the vasodilatory effect of nitrite has been widely studied, the
effect of nitrite on platelet activity has received much less
attention so far. Nitrite at a high concentration (500 mM)
was reported to inhibit ADP-induced platelet aggregation
and to increase cyclic guanosine monophosphate (cGMP)
(Laustiola 1991), suggesting that the effects of nitrite on plate-
lets are mediated by NO and the subsequent activation of
guanylyl cyclase. The elevation in plasma nitrite levels fol-
lowing the ingestion of a nitrate-rich diet was reported to
reduce blood pressure and attenuate the platelet aggregation
induced by ADP and collagen in plasma, supporting the im-
portance of nitrite’s effects on platelet activity in humans
Fig. 4 Ex vivo effects of nitrate
and nitrite on a fibrin generation
and b area under the curve (AUC)
in hypertensive (2K1C) rats (oral
administration twice daily for
3 days, 0.17 mmol/kg); *p < 0.05,
**p < 0.01 vs. VEH
Table 1 Effects of nitrate and
nitrite on clotting parameters in rats VEH (2K1C) 3 days NaNO2 0.17
mmol/kg
3 days NaNO3 0.17
mmol/kg
PT [s] 18.1 ± 0.2 19.5 ± 0.6* 18.6 ± 0.4
aPTT [s] 19.1 ± 0.4 18.7 ± 0.6 18.5 ± 0.7
Fg [ng/ml] 2.5 ± 0.1 2.5 ± 0.1 2.4 ± 0.04
QUICK 58.6 ± 2.0 55.0 ± 4.1 57.5 ± 2.6
PT prothrombin time, APTT activated partial thromboplastin time, Fg fibrinogen level, QUICK percentage index
of prothrombin time (Quick index)
*p < 0.05 vs. VEH
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(Webb 2008). In our experiments in rats, we have clearly
demonstrated that nitrite inhibits platelets ex vivo, i.e., inhibits
collagen-induced platelet aggregation in whole blood, as well
as decreases dynamic generation of TxB2. Since arterial
thrombosis is strongly platelet-dependent (Kramkowski
2010; Pruolle 2014), our experiments suggest that nitrite’s
strong antithrombotic effects are mediated in large part by
inhibition of platelets. Indeed, using real-time intravital con-
focal visualization of thrombosis, we observed highly dimin-
ished platelet accumulation after laser injury to the endotheli-
um in mice treated with nitrite. In the same model, nitrate was
without effect on platelets.
Altogether, our results suggest that nitrite induces profound
NO-dependent antithrombotic effects with short-term treat-
ment in vivo. However, the conversion of nitrate to nitrite in
rats and mice was not sufficient to elicit NO-dependent anti-
platelet and antithrombotic effects over the short-term period
of nitrate treatment shown to be effective in humans (Larsen
2006).
Accordingly, effects of nitrite in rats and mice seem to be
similar to those described in humans, including antiplatelet
effects mediated by NO (Lasrsen 2006; Webb 2008). On the
other hand, we did not observe pharmacologically important
antiplatelet or antithrombotic effects of nitrate, underscoring
the differences in metabolism between nitrate and nitrite in
rats and mice, as compared to humans.
In humans, the half-life of an oral dose of inorganic nitrate
is surprisingly long, ranging between 5 and 8 h. On the other
hand, nitrate is instantly converted to nitrite, so the increase in
plasma nitrite concentration parallels the increase in plasma
nitrate concentration (Larsen 2011). It was suggested that the
increase in nitrite after nitrate administration is entirely due to
enterosalivary circulation of nitrate and nitrate’s reduction to
nitrite by commensal bacteria in the mouth (Lundberg 2010).
Fig. 5 Effects of nitrate and
nitrite on a kinetics of platelet
accumulation in the area of laser-
injured endothelium in GFP mice
and b area under the curve (AUC)
(oral administration for twice
daily for 3 days, 0.17 mmol/kg)
Table 2 Effects of nitrate and
nitrite on blood cell count in rats VEH (2K1C) NaNO2 3 days 0.17
mmol/kg
NaNO3 3 days 0.17
mmol/kg
WBC [106/μl] 3.33 ± 0.18 2.70 ± 0.19 3.00 ± 0.35
RBC [106/μl] 7.51 ± 0.2 7.10 ± 0.27 7.10 ± 0.10
HGB [g/dl] 13.59 ± 0.35 13.25 ± 0.4 13.23 ± 0.27
HCT [%] 41.58 ± 1.07 40.00 ± 1.52 40.68 ± 1.55
MCV [fl] 55.42 ± 0.31 56.33 ± 0.71 57.5 ± 0.50*
MCH [pg per cell] 18.13 ± 0.15 18.68 ± 0.28 18.68 ± 0.25
MCHC [g/dl] 32.68 ± 0.15 33.17 ± 0.63 32.60 ± 0.45
PLT [103/μl] 623 ± 24 650 ± 31 669 ± 52
WBCwhite blood cells,RBC red blood cells,HGB hemoglobin,HCT hematocrit,MCVmean corpuscular volume,
MCH mean corpuscular hemoglobin,MCHC mean corpuscular hemoglobin concentration, PLT platelets
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In our previous paper, we have demonstrated that XOR was
involved in nitrite reduction into NO in rats (Kramkowski
2015). Here, we did not study the mechanism of nitrite reduc-
tion, but we believe that XOR could be involved not only in
rats but also in mice, as XOR displays substantially higher
activity in rodents as compared to human (Cantu-Medellin
2013a,b). On the other hand, unlike in vitro hypoxic condition
(Millar 1998), it is unlikely that XOR contributed to nitrate
reduction as the conversion of nitrate to nitrite was minimal
either in rats or in mice.
In our study, we administered sodium nitrate or sodium
nitrite directly into the stomach, which resulted in elevated
plasma nitrate concentrations. As mentioned, in humans, the
most important chemical step of this “circulation” is nitrate
uptake by the salivary glands, followed by reduction via com-
mensal facultative anaerobic bacteria. In rats, nitrate-reducing
bacteria was similarly found on rat tongue, with bacterial den-
sity increasing in the direction of the posterior tongue (Li
1997). Interestingly, Hyde et al. (2014) showed that supple-
mentation with nitrate in a high amount (1 g/l) for 7 days in
drinking water resulted in a substantial decrease in blood pres-
sure and changes in rat tongue bacterial flora. These changes
included a significant increase in nitrate-reducing taxas, for
example, Haemophilus parainfluenzae, Granulicatella, and
Aggregatibacter. Accordingly, it seems that high nitrate diets
may induce changes in the oral microbiome, so as to more
efficiently reduce nitrate to nitrite and NO (Hyde 2014).
These results are in line with our studies showing that nitrate
administered for 10 days at a dose of 0.17 mmol/kg daily
decreased thrombus weight to 65 % of control (p < 0.05)
(Kramkowski 2013). However, as demonstrated in the present
work, short-term 3-day supplementation with nitrate
(0.17 mmol/kg) was not sufficient to induce NO-dependent
pharmacological effects, most likely because the
microbacterial flora of the rats and mice used in our experi-
ments could not sufficiently reduce nitrate to nitrite.
It was recently demonstrated that long-term supple-
mentation of drinking water with dietary nitrate reduced
stress-induced gastric damage in the bilateral parotid and
submandibular gland duct ligature in rats (BPSDL) (Jin
2013). That ligature completely blocked nitrate secretion
by the salivary glands, resulting in decreased gastric ni-
trate (60 %), nitrite (66 %), and NO (62 %) concentra-
tions. After nitrate supplementation in the drinking water
for 1 week, the nitrate and nitrite levels in the fasting
gastric juice increased. A similar pattern was observed
for the level of luminal NO, which was increased by
1000 %. Most importantly, administration of nitrate sig-
nificantly reduced stress-induced gastric ulcers in BPSDL
rats, supporting the notion that the protective effect of
nitrate in rats involves enterosalivary circulation.
However, nitrate conversion into nitrite through the
enterosalivary circulation system seems to require a long
period of nitrate exposure to induce the ecological selec-
tion of nitrate-consuming bacteria in the gavage. This
condition might not be present in the experimental rats
or mice fed a standard laboratory animal diet and kept in
sterile environment in animal house.
In summary, we have confirmed that nitrite induces pro-
found NO-dependent antithrombotic effects in vivo in mice
and rats. However, the conversion of nitrates to nitrite in rats
and mice upon short-term 3-day treatment was not sufficient
to elicit NO-dependent antiplatelet and antithrombotic effects.
This is most likely due to less efficient enterosalivary circula-
tion and sparse microbacterial flora to reduce nitrate to nitrite
in rats and mice as opposed to humans, in whom acute NO-
dependent effects of nitrate have been demonstrated (Kapil
2013).
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